CD47 expression is increased in HSCs after mobilization or induced inflammation
Mobilization of marrow stem and progenitor cells involves several steps in which they come into contact with macrophages. We thus utilized the cyclophosphamide/G-CSF (Cy/G) protocol (Morrison et al., 1997
) to experimentally induce mobilization in mice. We found that there was a notable increase of CD47 on c-Kit+ bone marrow cells on day 2 (), when bone marrow HSC reach their maximum level, with CD47 increasing approximately four-fold by this time point (). The increase was seen at all levels of the myeloid progenitor hierarchy, as LT-HSCs as well as GMPs displayed this increase in CD47 expression (). By day 5, when egress from the marrow to distant marrow/spleen/liver sites had nearly stopped, the levels of CD47 on the marrow HSC/progenitors had returned to nearly normal levels. In , the mean fluorescence intensity of CD47 expression on GMPs is shown on days 0 to 5 of mobilization.
Mobilization or inflammation induces CD47 up-regulation in hematopoietic stem and progenitor cells
These results predicted that mobilized human HSC in the blood would also have increased levels of CD47 on their cell surface. We examined the CD47 expression level on human bone marrow, cord blood, (CB) and mobilized peripheral blood (MPB) HSCs. The results show that human HSCs in circulation have significantly higher levels of CD47 expression than sessile HSCs ().
Endotoxins such as LPS are also thought to contribute to bone marrow mobilization (Cline and Golde, 1977
) by causing activation of macrophages and a pro-inflammatory response (Fenton and Golenbock, 1998
), as well as increasing the phagocytic capacity of macrophages (Wright et al., 1989
). We tested whether LPS administration in mice would affect CD47 expression in stem and progenitor cells. Mirroring the pattern seen in Cy/G induced mobilization, LPS caused expansion of stem and progenitor cells by 2 days post treatment, followed by migration to the spleen and liver (). On day 2 after LPS administration, stem and progenitor cells in the marrow had up-regulated CD47 to a similar degree as in Cy/G mobilization. By day 5, when the inflammatory response had resolved, the levels of the protein had dropped to steady-state levels ().
CD47 up-regulation during mobilization is unlikely to be necessary for migration
Since CD47 was consistently up-regulated in the mobilization response, we tested the ability of stem and progenitor cells to mobilize following Cy/G. The CD47 knockout mouse has defects in migration of neutrophils to sites of inflammation (Lindberg et al., 1996
) and of dendritic cells to secondary lymphoid organs (Van et al., 2006
). The exact role of CD47 in migration of these cells is unknown, but it may relate to poor integrin binding in the circulation or lack of interaction with SIRPα on endothelial cells. Hence we reasoned that if CD47 was involved in the migration capacity of these cells during mobilization, then IAP-/- mice would display reduced numbers of cells in the peripheral organs after Cy/G.
We thus administered Cy/G to both wild-type and knockout mice and sacrificed mice on days 2-5. For each mouse, we analyzed the number of stem and progenitor cells in peripheral blood, marrow, spleen, and liver. We used the KLS population as a surrogate for HSCs because the number of CD34- cells drops considerably in proliferative states, making accurate calculation of LT-HSC numbers difficult.
We found that there was little difference in numbers of mobilized KLS or GMP between wild-type and IAP-/- mice (). There was a modest decrease in the ability of IAP-/- mice to move progenitors to the spleen by day 3 (about 10 fold less), but by days 4 and 5 they had restored normal numbers of cells to the periphery. The marrow and liver compartments in IAP-/- had no difference in HSC or GMP from wild-type mice. Additionally, there was no difference in HSC numbers in peripheral blood by day 4 (data not shown). Hence, IAP-/- mice do not have a significant mobilization defect. While this result does not support a role for CD47 in the migration phase of mobilization, it does not rule out a role for protection against phagocytosis since macrophages from IAP-/- mice also fail to properly phagocytose CD47 deficient cells, likely due to aberrant macrophage education (Wang et al., 2007
CD47 deficient mice have no gross hematopoietic defect but IAP-/- HSCs fail to engraft wild-type mice
We examined stem and progenitor frequencies in IAP+/- and IAP-/- mice. The relative frequency of cells in the stem and myeloid progenitor compartment did not differ between these mice and wild-type mice (). We then tested stem cells from these mice for their ability to form colonies in an in vitro assay. We examined colony formation at day 7 and found that there was no major difference between wild-type and IAP-/- stem cells in the number and type of colonies formed ().
CD47 deficient HSCs are efficiently phagocytosed by macrophages but otherwise exhibit normal hematopoietic developmental potential
We also tested whether bone marrow cells from IAP-/- mice could rescue recipient mice from the effects of lethal irradiation. Typically, a dose of 2 × 105
bone marrow cells will rescue 100% of recipient mice in this assay. In agreement with previous results (Blazar et al., 2001
), we found that IAP-/- bone marrow could not rescue these recipients (). However, administration of these cells did prolong lifespan; normally, mice die between day 12 and 15 after irradiation, but mice that received IAP-/-bone marrow lived about 7 to 10 days longer (). We do not yet know the reason for the prolongation of lifespan in this case.
Next, we sorted Flk-2- CD34- KLS stem cells from wild-type and IAP-/- cells and transplanted them into lethally irradiated wild-type recipients along with 2 × 105
competitor cells. None of the mice which received IAP-/- HSCs had any engraftment of donor cells, indicating that CD47 was indeed required to be expressed intrinsically for the HSC to transplant (). We speculated that this was due to phagocytosis of CD47 null cells, as has been shown for erythrocytes and T-cells. To test this, we enriched c-Kit+ cells from the bone marrow of wild-type and IAP-/- mice and co-incubated them with bone marrow derived macrophages. IAP-/- stem and progenitor cells were readily phagocytosed in this assay, whereas wild-type cells were only minimally phagocytosed (). These results were not due to increased apoptosis of the IAP-/- cells in these culture conditions, as there was no difference in Annexin V positivity between the groups (Supplementary Figure 4a
We also tested HSC migration using the parabiosis model in which two mice are joined surgically to allow their circulatory systems to form anastamoses and a shared blood system (Wright et al., 2001b
). This model allows the examination of migration in a more physiological setting since stem cells are continuously seeded into the blood stream from the marrow over time. We joined an IAP-/- mouse with a congenic wild-type GFP+ mouse. For both pairs of mice that were parabiosed, bone marrow HSC chimerism was seen in the IAP-/- mouse, but not the wild-type mouse (Supplementary Figure 1
). Thus, IAP-/- HSCs are cleared even during physiological migration.
CD47 heterozygous HSCs have reduced fitness relative to wild-type HSCs due to macrophage clearance
Our observation that CD47 expression increasea in states of stress and mobilization led us to hypothesize that HSPCs that were genetically hemizygous for CD47 might be more prone to phagocytosis and clearance by macrophages over time, as has been seen for platelets and erythrocytes (Olsson et al., 2005
; Olsson et al., 2007
). Hence, we asked if IAP+/- stem cells would be disadvantaged relative to wild-type stem cells in long-term contribution to hematopoiesis. We first analyzed the levels of CD47 expressed on IAP+/+, IAP+/-, and IAP-/- stem cells. FACS analysis of CD34- Flk-2-KLS stem cells revealed that the MFI of CD47 on heterozygote HSCs was indeed at roughly half the level of wild-type stem cells ().
IAP+/- HSCs have a competitive disadvantage relative to wild-type HSCs due to macrophages
We then transplanted one cohort of sub-lethally irradiated recipients with 2 × 106
wild-type whole bone marrow cells, and another with the same dose of IAP+/- bone marrow cells. Such a dose would be expected to contain roughly 50-100 HSCs. Since granulocyte chimerism in the peripheral blood is a good surrogate marker of stem cell fitness (Bhattacharya et al., 2006
), we analyzed cells from the blood of these recipients at periodic intervals. When wild-type marrow was transplanted into wild-type recipients, granulocyte chimerism was maintained for at least 40 weeks. However, when IAP+/-cells were transplanted, 4 out of 10 mice lost donor chimerism over time, despite having a successful engraftment initially (p=0.0297, , Supplementary Figure 2a
). It was possible that there were fewer LT-HSC per unit of marrow in IAP+/- or IAP-/- mice compared to wild-type. To test if IAP-/- mice had fewer functional HSC, we transplanted either IAP+/+ or IAP-/- marrow cells into IAP-/- donors. We also co-transplanted IAP+/-marrow into wild-type mice together with wild-type marrow. We did not find any statistical difference in donor granulocyte chimerism for up to 12 weeks in either case (Supplementary Figures 2b-c
) indicating that there was not a demonstrable deficit in stem cell numbers in IAP+/- or IAP-/- mice.
Interestingly, the IAP+/- chimeras that did not lose donor engraftment over time did not appear to have a quantitative deficit in chimerism; rather they seemed to have similar levels of donor cells as the wild-type chimeras (Supplementary Figure 2a
). We thus hypothesized that physiological insults leading to chronic or acute inflammatory states that occurred in some mice, but not others, led to their losing IAP+/- donor chimerism over time, but at steady state the donor IAP+/- cells were not affected.
To test this, we created chimeras by transplanting whole bone marrow from either IAP+/+ GFP+ or IAP+/- GFP+ mice into sub-lethally irradiated wild-type syngeneic recipients. Since IAP-/- mice have no known in vivo
(Lindberg et al., 1996
) or in vitro
() defect in granulopoiesis, blood granulocyte chimerism, can be used in this setting to estimate donor HSC engraftment. After 12 weeks, contribution of donor HSCs was assessed. At this early time point, IAP+/- mice actually had a higher blood granulocyte contribution, but there was considerable variation within each group. The mice were challenged with a sublethal dose of LPS (day 0), then given clodronate or control lipsomes on day 2 and day 7. Clodronate liposomes have been shown to specifically but transiently deplete marrow, spleen, and liver macrophages when injected intravenously (Van Rooijen and Sanders, 1994
). At day 14, the mice were euthanized and actual marrow KLS chimerism was assessed and compared to expected chimerism based on blood granulocyte chimerism (). Raw values are shown in Supplementary Table 1
. The results indicate that there were more host (wild-type) KLS cells in the bone marrow of the IAP+/- chimeras than expected. When macrophages were depleted, the chimerism was at the level that would be expected based on blood granulocyte chimerism. ANOVA showed a significant interaction among IAP genotype (IAP+/+ vs. IAP +/-) and treatment with and without clodronate (CLOD vs. CTRL) (p=0.0069). When the group including the IAP+/- chimeras treated with control liposomes (IAP+/- CTRL) was excluded, there was no statistical difference between the groups (p=0.28). Analysis also showed that differences between the treatment with and without clodronate were not significant in IAP+/+ mice (p=0.20), but were significant in IAP +/- mice (p=0.011).
It was possible that these results were due to increased apoptosis of IAP+/- cells relative to IAP+/+. To test this, we measured the percent of Annexin V+ 7-AAD- KLS cells in IAP+/+ and IAP+/- mice treated with LPS in the presence of control or clodronate liposomes. There was no difference between the groups (Supplementary Figure 4b
To establish that macrophages were indeed responsible for clearing the cells with reduced CD47 expression, we challenged donor IAP+/+, GFP+ and IAP+/-, GFP+ mice with LPS. After 3 days, we harvested bone marrow from these mice and transplanted c-Kit enriched cells intra-splenically into GFP-negative wild-type recipient mice similarly challenged with LPS 3 days prior. After 2 hours the recipient spleens were harvested and analyzed by FACS. There were significantly more F4/80+ macrophages that were GFP+ (representing macrophages containing phagocytosed GFP+ cells) in mice injected with IAP+/- cells compared to IAP+/+ (p<0.0001, , Supplementary Figure 3
CD47 is up-regulated on mouse myeloid leukemias
Previous microarray analysis had revealed that CD47 was significantly up-regulated in leukemic Faslpr/lpr
× hMRP8bcl2 transgenic bone marrow (Traver et al., 1998
) and this was confirmed in leukemic hMRP8bcr/abl × hMRP8bcl2 mice (Jaiswal et al., 2003
). Transcripts for CD47 were found to be increased in leukemic hMRP8bcr/abl × hMRP8bcl2 bone marrow 3-4 fold by quantitative RT-PCR and 6-7 fold in c-Kit enriched leukemic marrow relative to healthy hMRP8bcl2+ bone marrow (). Leukemic mice had an expansion of the granulocyte macrophage progenitor (GMP) population as well as c-Kit+ Sca-1+ Lin-stem and progenitor subsets in the spleen relative to control mice, which were of the same genotype as leukemic mice but failed to develop disease (). Expression levels for CD47 protein were found to begin increasing in leukemic mice relative to control mice at the stage of the Flk2- CD34- c-Kit+ Sca-1+ Lin- long-term hematopoietic stem cell (LT-HSC) () (Yang et al., 2005
). This increased level of expression was maintained in GMP and Mac-1+ blasts, but not megakaryocyte/erythroid restricted progenitors (MEP) (). The increase in CD47 surface expression between leukemic and normal cells was between 3 to 20 fold, depending on the sample and fluorophore used (Supplementary figure 5c
). We have observed increased CD47 expression in all mice that developed leukemia from hMRP8bcr/abl × hMRP8bcl2 primary (n=3) and secondary transplanted mice (n=3), Fas lpr/lpr
× hMRP8bcl2 (Supplementary figure 4a
) primary (n=14) and secondary (n=19) mice, and hMRP8bcl2 × hMRP8bcl2 primary (n=3) and secondary (n=12) mice. We have also found increased CD47 expression in mice that received p210bcr/abl retrovirally-transduced mouse bone marrow cells that developed leukemia (Supplementary figure 5b
CD47 is up-regulated in murine and human myeloid leukemia
CD47 expression on normal and leukemic human stem cells
Because we found CD47 to be increased on all mouse leukemias we examined, we investigated CD47 expression on normal and dysplastic human hematopoietic cells. FACS-mediated analysis of human hematopoietic progenitor populations was performed on blood and marrow derived cells from normal cord blood and mobilized peripheral blood (n=16) and myeloproliferative disorders (MPDs) including polycythemia vera (PV; n=16), myelofibrosis (MF; n=5), essential thrombocythemia (ET; n=7), chronic myelomonocytic leukemia (CMML; n=11) and atypical chronic myeloid leukemia (aCML; n=1) as well as myeloid blast crisis [BC] phase chronic myeloid leukemia (CML; n=19), chronic phase CML (n=7) and acute myelogenous leukemia (AML; n=13). This analysis demonstrated that the granulocyte-macrophage progenitor (GMP) population was expanded in MPDs with myeloid skewed differentiation potential including atypical CML, proliferative phase CMML and acute leukemia including blast crisis CML and AML (Supplementary figure 6a, 6c
). AML HSC and progenitors uniformly exhibited higher levels of CD47 expression compared with normal controls (); every sample from CML-BC (n=19) and AML (n=13) had elevated levels of CD47. Moreover, progression from chronic phase CML to blast crisis was associated with a significant increase in CD47 expression (). Using the methods described in this study, we have found that human CD47 protein expression in CML-BC increased 2.2 fold in CD90+ CD34+ CD38- Lin- cells relative to normal CB and MPB (p=6.3 × 10-5
), 2.3 fold in CD90- CD34+ CD38- Lin- cells relative to normal (p=4.3 × 10-5
), and 2.4 fold in CD34+ CD38+ Lin- cells (p=7.6 × 10-6
) (, Supplementary Figure 6b
). Since CB and MPB HSCs have almost double the amount of CD47 as normal marrow (), these figures likely underestimate the true increase in CD47 compared to normal marrow.
We also examined CD47 expression in other myeloproliferative disorders, such as polycythemia vera, post-polycythemic myeloid metaplasia with myelofibrosis, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelomonocytic leuekmia. None of the samples we examined from these disorders displayed increased CD47 (data not shown). It is likely that the fixed, high expression of CD47 on AML cells and CML-BC cells represents a late event in malignant progression, whether by genetic or epigenetic heritably increased expression. A summary of all the human samples analyzed is shown in Supplementary Table 2
CD47 expression can rescue the in vivo growth defect of the AML cell line MOLM-13 via a mechanism other than migration
In order to experimentally test the significance of elevated CD47 expression on myeloid leukemias, we decided to examine whether the level of CD47 expressed on myeloid leukemia could affect its pathogenicity in vivo
. We first screened a panel of human AML cell lines for human CD47 expression. On the basis of this analysis, we found significant variation in the amount of cell surface CD47 (adjusted for cell size) in the varying lines (Supplementary Figures 7a-b
). We then tested whether there was variation in the ability of some of these cell lines to engraft in immunocompromised mice. Human HL-60 and Kasumi-1 cells, which express moderate to high levels of human CD47, were able to engraft C57Bl/6 or Balb/c recombination activating gene 2, common gamma chain deficient (RAG2-/-, γc-/-) mice (Supplementary Figures 6c-d
), which are reported to have little or no interaction between their SIRPα and human CD47 (Takenaka et al., 2007
). MOLM-13 cells, which are derived from a patient with AML 5a, have low endogenous CD47 expression and were unable to engraft in either of these strains. Even when transplanted into non-obese diabetic severe combined immunodeficiency, interleukin 2 receptor common gamma chain -/- (NOG) mice that are reported to have more effective interaction between their mouse SIRPα and human CD47, and thus should be permissive for human donor cells (Takenaka et al., 2007
), MOLM-13 cells failed to engraft (Supplementary Figure 7c
Since MOLM-13 cells failed to engraft in any of the mouse models tested, we decided to use them for further analysis of the role of CD47 in leukemogenicity. MOLM-13 cells were transduced with either control (Tet) or CD47 expressing (Tet-CD47) lentiviruses (), and stable integrants were propagated on the basis of GFP expression. We first tested if ectopic expression of the murine CD47 (muCD47) protein could rescue the growth defect of these cells. The cells were transplanted intravenously in a competitive setting with untransduced MOLM-13 cells into T, B, and NK deficient RAG2-/-, γc-/- mice. Only cells transduced with Tet-CD47 were able to give rise to tumors in these mice, efficiently engrafting bone marrow, spleen, liver, and peripheral blood ().
Over-expression of murine CD47 rescues the growth defect of MOLM-13 myeloid leukemia cells
Since CD47 has been reported to be important for the migration of hematopoietic cells, one possibility for the lack of growth of Tet MOLM-13 cells in mice was their inability to migrate to niches. To test this, Tet MOLM-13 or Tet-CD47 MOLM-13 cells were directly injected into a single femoral cavity of immunodeficient Balb/c mice. Tet-CD47 MOLM-13 cells were able to spread to all bones and other hematopoietic tissues of recipient mice and lead to death, whereas Tet MOLM-13 cells had minimal, if any, engraftment, and only at the site of injection, without morbidity by 75 days after transplant (). These results suggested a function other than or in addition to migration for CD47 in MOLM-13 engraftment.
The level of CD47 expressed on MOLM-13 cells determines tumorigenic potential
Our results up to this point had indicated that ectopically expressing muCD47 on a non-engrafting human cell line could rescue its growth defect. These experiments did not, however, answer whether the level of CD47 expressed on a leukemic cell could affect its tumor forming potential. To model the tumorigenic effect of having high versus low CD47 expression, we sorted clones of muCD47 expressing MOLM-13 cells into high and low expressors. When adjusted for cell size, CD47 density on the CD47lo MOLM-13 cells was approximately equal to mouse bone marrow cells, whereas CD47hi MOLM-13 cells had 9-fold higher expression, an increase commensurate with the change seen in CD47 expression on primary leukemic cells compared to their normal counterparts (). When high or low expressing cells were transplanted into recipients, only mice transplanted with high expressing cells succumbed to disease by 75 days of age (). Furthermore, organomegaly was more pronounced in these mice(). As expected, the infiltration of MOLM-13 cells in bone marrow and spleen of recipient mice was also much higher for mice transplanted with CD47hi MOLM-13 cells as well (). We also examined the level of CD47 expression in two mice that received CD47lo MOLM-13 cells but had significant marrow engraftment. In both cases, the persisting cells after 75 days had much higher levels of CD47 than the original line (), indicating that a strong selection pressure exists in vivo for high levels of CD47 expression on MOLM-13 leukemia cells.
Higher expression of CD47 on MOLM-13 cells causes increased tumorigenicity
We were also able to modulate CD47 expression with doxycycline since we utilized the Tet-responsive (Tet-OFF) promoter element to control expression of CD47 in MOLM-13 cells. Beginning two weeks after transplantation with CD47hi MOLM-13 cells, a cohort of mice was given doxycycline to extinguish CD47 expression and followed for up to 75 days post-transplant. During this time, none of the mice given doxycycline succumbed to disease or had large infiltration of MOLM-13 cells in hematopoietic organs () other than 1-2 large extra-parenchymal masses seen in the livers. At the dose of doxycycline used in this experiment, muCD47 expression in MOLM-13 cells was reduced to levels below that of normal mouse bone marrow, but notably not completely absent (). Thus, a sustained high level of CD47 expression is required for robust MOLM-13 growth in hematopoietic organs.
Macrophages mediate selective pressure for CD47hi variants of MOLM-13 cells
Since we had observed that mice transplanted with CD47lo MOLM-13 cells had selection over time for higher expressing clones in vivo, we wondered if this selection pressure was mediated by macrophages. To test this, we used clodronate liposomes to deplete macrophages prior to and after transplant of CD47lo MOLM-13 cells and sacrificed mice after 5 weeks. When control liposomes were used, the level of CD47 increased significantly on the engrafted human cells. However, when clodronate containing liposomes were used, the expression of CD47 on MOLM-13 cells was maintained at the level of the parental line (). Thus, macrophages mediate selective pressure for high expressing CD47 clones in vivo.
Interestingly, when clodronate was used to deplete macrophages in the immunodeficient mice, the level of engraftment was comparable between the control Tet MOLM-13 cells and the CD47 MOLM-13 cells (Supplementary Figure 8
) suggesting that depletion of macrophages could compensate for lack of CD47 expression on MOLM-13 cells as well.
Ability to evade macrophage phagocytosis correlates with CD47 expression level
We incubated Tet (vector only), bulk (unsorted) Tet-CD47, Tet-CD47hi
, or Tet-CD47lo
MOLM-13 cells with bone marrow derived macrophages (BMDM) for 2-24 hours and assessed phagocytosis by counting the number of ingested GFP+ cells under a microscope () or by evaluating the frequency of GFP+ macrophages by flow cytometry (Supplementary Figure 9a
). There was a strong correlation between level of CD47 expressed and the likelihood of phagocytosis (). When CD47lo
RFP and CD47hi
GFP MOLM-13 cells were co-incubated with macrophages in the same wells, the low expressing cells were far more likely to be phagocytosed (). Thus, in a mixed population of cells with varying levels of CD47 expression, the low expressiors were more likely to be cleared by macrophages over time. These results were not due to differences in apoptosis between CD47 expressing and control MOLM-13 cells, as both groups had similar levels of Annexin V positivity in vitro
(Supplementary Figure 4c
Increasing CD47 expression on MOLM-13 cells confers increasing ability to evade macrophage phagocytosis
We also injected MOLM-13 cells into mice and analyzed hematopoietic organs 2 hours later for evidence of macrophage phagocytosis. Macrophages in bone marrow, spleen, and liver all had a higher GFP+ fraction when injected with Tet MOLM-13 cells as compared to muCD47 expressing cells, indicating that the muCD47- cells were more likely to be phagocytosed in vivo
as well (Supplementary Figure 9b
Finally, we asked if inhibiting macrophage SIRPα using a blocking antibody could abrogate the protection against phagocytosis that CD47 provided MOLM-13 cells. Indeed, when this receptor was blocked, CD47 expressing MOLM-13 cells were phagocytosed at the same rate as control MOLM-13 cells (Supplementary Figure 10